Conference item icon

Conference item

A novel phase 1 trial design to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TOP1288, a narrow spectrum kinase inhibitor, delivered topically to the colon via oral administration

Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1093/ecco-jcc/jjx180.486

Authors


Expand authors...
Publisher:
Oxford University Press Publisher's website
Journal:
Journal of Crohn's and Colitis Journal website
Volume:
12
Issue:
supplement_1
Pages:
S285–S286
Host title:
Journal of Crohn's and Colitis
Publication date:
2018-01-16
Acceptance date:
2018-01-16
DOI:
EISSN:
1876-4479
ISSN:
1873-9946
Source identifiers:
844217
Pubs id:
pubs:844217
UUID:
uuid:389cc7fa-f070-411b-ac12-938f49894513
Local pid:
pubs:844217
Deposit date:
2018-09-23

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP